The integration of immune gene expression profiles into current algorithms for risk-stratification, which predominantly rely on ELN cytogenetic risk categories, may allow the identification of patient subgroups with “inflamed” or hot AML, who could be amenable to ICB and other immunotherapy approaches, incuding the use of bispecific CD3 × CD123 molecules and small-molecule IDO1 inhibitors (Figure 3). This evidence concerns the gene IDO1 and acute myeloid leukemia.